nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-5-54-64nnp-2105Research ArticleREVIEWSОБЗОРЫDepressive disorders and their pharmacotherapy in routine clinical practiceДепрессивные расстройства и их фармакотерапия в рутинной клинической практикеhttps://orcid.org/0000-0002-5749-3964МосоловС. Н.MosolovS. N.

119034, Москва, Кропоткинский пер., 23; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

23, Kropotkinskiy Lane, Moscow 119034; 2/1, Barrikadnaya St., Build. 1, Moscow 125993

https://orcid.org/0000-0002-1992-7960ПарфеновВ. А.ParfenovV. A.

Владимир Анатольевич Парфенов - кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского.

119021, Москва, ул. Россолимо, 11, стр. 1

Vladimir Anatolyevich Parfenov - Department of Nervous Diseases and Neurosurgery.

11, Rossolimo St., Build. 1, Moscow 119021

vladimirparfenov@mail.ruhttps://orcid.org/0000-0001-6437-232XАмелинА. В.AmelinA. V.

Кафедра неврологии.

197022, Санкт-Петербург, ул. Льва Толстого, 6–8

Department of Nevrology.

6-8, L’va Tolstogo St., St. Petersburg 197022

https://orcid.org/0000-0001-8653-596XМедведевВ. Э.MedvedevV. E.

Кафедра психиатрии, психотерапии и психосоматической патологии факультета непрерывного медицинского образования Медицинского института.

117198, Москва, ул. Миклухо-Маклая, 6

Department of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education.

6, Miklukho-Maklaya St., Moscow 117198

МенделевичВ. Д.MendelevichV. D.

420012, Казань, ул. Бутлерова, 49

49, Butlerova St., Kazan 420012

https://orcid.org/0000-0002-7619-1179УсовГ. М.UsovG. M.

644099, Омск, ул. Ленина, 12

12, Lenina St., Omsk 644099

https://orcid.org/0000-0002-4494-149XСиволапЮ. П.SivolapYu. P.

Кафедра психиатрии, психотерапии и психосоматической патологии факультета непрерывного медицинского образования Медицинского института.

117198, Москва, ул. Миклухо-Маклая, 6

Department of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education.

6, Miklukho-Maklaya St., Moscow 117198

https://orcid.org/0000-0002-6327-3546БоголеповаА. Н.BogolepovaA. N.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10

1, Ostrovityanova St., Moscow 117997; 21, Ostrovityanova St., Build. 10, Moscow 117997

https://orcid.org/0000-0003-2597-981XМхитарянЭ. А.MkhitaryanE. A.

129226, Москва, ул. 1-я Леонова, 16

16, 1st Leonova St., Moscow 129226

https://orcid.org/0000-0002-2228-6316ПетелинД. С.PetelinD. S.

Кафедра психиатрии и психосоматики лечебного факультета Первый МГМУ им. И.М. Сеченова.

119991, Москва, ул. Трубецкая, 8, стр. 2; 115552, Москва, Каширское шоссе, 34

Department of Psychiatry and Psychosomatics I.M. Sechenov First MSMU.

8, Trubrtskaya St., Build. 2, Moscow 119991; 1234, Kashirskoe Sh., Moscow 115522

ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.P. Serbsky National Medical Research Center of Psychiatry and Narcology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional EducationRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияAcad. I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»РоссияPatrice Lumumba Peoples' Friendship University of Russia (RUDN University)Russian FederationГБОУ ВПО «Казанский государственный медицинский университет» Минздрава РоссииРоссияKazan State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of RussiaRussian FederationРоссийский геронтологический научно-клинический центр ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияRussian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); ФГБНУ «Научный центр психического здоровья»РоссияN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Mental Health Research CenterRussian Federation2023231020231555464Copyright © Mosolov S.N., Parfenov V.A., Amelin A.V., Medvedev V.E., Mendelevich V.D., Usov G.M., Sivolap Y.P., Bogolepova A.N., Mkhitaryan E.A., Petelin D.S., 20232023Мосолов С.Н., Парфенов В.А., Амелин А.В., Медведев В.Э., Менделевич В.Д., Усов Г.М., Сиволап Ю.П., Боголепова А.Н., Мхитарян Э.А., Петелин Д.С.Mosolov S.N., Parfenov V.A., Amelin A.V., Medvedev V.E., Mendelevich V.D., Usov G.M., Sivolap Y.P., Bogolepova A.N., Mkhitaryan E.A., Petelin D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2105

Depression is one of the most common medical causes of disability and mortality in patients of all ages. Depressive disorders are common in the practice of physicians of a variety of specialties, including psychiatrists, neurologists, and physicians. This paper provides a summary review of the literature on modern ideas about the epidemiology, classification, and clinical picture of depression. Current approaches to the diagnosis and treatment of depressive disorders in neurological and psychiatric practice are discussed. Modern pharmacotherapeutic strategies for the treatment of depression in various patient populations are described in detail. Current clinical practice indicates the high importance of an interdisciplinary approach in the diagnosis and management of patients with depressive symptoms in Russia. The paper suggests organizational and educational strategies that can be recommended to improve the effectiveness of medical care for patients with depressive disorders.

Депрессия является одной из ведущих медицинских причин инвалидизации и смертности среди пациентов всех возрастных групп. Депрессивные расстройства могут встречаться в практике врачей разных специальностей, как психиатров, так и неврологов и терапевтов. В настоящей работе приведен краткий обзор литературы, посвященной современным представлениям об эпидемиологии, классификации, клинической картине депрессии. Рассматриваются актуальные подходы к диагностике и терапии депрессивных расстройств в неврологической и психиатрической практике. Детально излагаются современные фармакотерапевтические стратегии лечения депрессий у различных групп пациентов. Текущая клиническая практика указывает на высокую значимость междисциплинарного подхода в диагностике и ведении пациентов с симптомами депрессии в России. В публикации предложены организационные и образовательные стратегии, которые могут быть рекомендованы для повышения эффективности оказания медицинской помощи пациентам с депрессивными расстройствами.

депрессияантидепрессантыселективные ингибиторы обратного захвата серотонинадепрессия с нарушениями снадепрессия с когнитивными нарушениямиdepressionantidepressantsselective serotonin reuptake inhibitorsdepression with sleep disordersdepression with cognitive impairmentИсследование не имело спонсорской поддержкиThe investigation has not been sponsoredReferencesDepression. Available from: https://www.who.int/news-room/factsheets/detail/depression (accessed 07.12.2022).Depression. Available from: https://www.who.int/news-room/factsheets/detail/depression (accessed 07.12.2022).Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-46. doi: 10.1001/jamapsychiatry.2017.4602Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-46. doi: 10.1001/jamapsychiatry.2017.4602Cuijpers P. The Challenges of Improving Treatments for Depression. JAMA. 2018 Dec 25;320(24):2529-30. doi: 10.1001/jama.2018.17824Cuijpers P. The Challenges of Improving Treatments for Depression. JAMA. 2018 Dec 25;320(24):2529-30. doi: 10.1001/jama.2018.17824COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-12. doi: 10.1016/S0140-6736(21)02143-7. Epub 2021 Oct 8.COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-12. doi: 10.1016/S0140-6736(21)02143-7. Epub 2021 Oct 8.Мосолов СН. Длительные психические нарушения после перенесенной острой коронавирусной инфекции SARS-CoV-2. Современная терапия психических расстройств. 2021;(3):2-23. doi: 10.21265/PSYPH.2021.31.25.001Mosolov SN. Long-term mental disorders after acute coronavirus infection SARS-CoV-2. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2021;(3):2-23. doi: 10.21265/PSYPH.2021.31.25.001 (In Russ.).Шальнова СА, Евстифеева СЕ, Деев АД и др. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социальнодемографическими факторами (по данным исследования ЭССЕ-РФ). Терапевтический архив. 2014;86(12):53-60. doi: 10.17116/terarkh2014861253-60Shal’nova SA, Evstifeeva ES, Deev AD, et al. The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study). Terapevticheskii arkhiv. 2014 Dec 15;86(12):53-60. doi: 10.17116/terarkh2014861253-60 (In Russ.).Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90Голенков АВ, Бонкало ТИ, Камынина НН, Шмелева СВ. Осведомленность населения о депрессии и методах ее лечения. Здравоохранение Российской Федерации. 2021;65(5):425-31.Golenkov AV, Bonkalo TI, Kamynina NN, Shmeleva SV. Population awareness of depression and treatment methods. Zdravookhranenie Rossiyskoy Federatsii. 2021;65(5):425-31 (In Russ.).Patel VL, Branch T, Mottur-Pilson C, Pinard G. Public awareness about depression: The effectiveness of a patient guideline. Int J Psychiatry Med. 2004;34(1):1-20. doi: 10.2190/YN2K-THQ1-33VA-HQMQPatel VL, Branch T, Mottur-Pilson C, Pinard G. Public awareness about depression: The effectiveness of a patient guideline. Int J Psychiatry Med. 2004;34(1):1-20. doi: 10.2190/YN2K-THQ1-33VA-HQMQTylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76. doi: 10.4088/pcc.v07n0405Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76. doi: 10.4088/pcc.v07n0405Dunne J, Flores M, Gawande R, Schuman-Olivier Z. Losing trust in body sensations: Interoceptive awareness and depression symptom severity among primary care patients. J Affect Disord. 2021 Mar 1;282:1210-9. doi: 10.1016/j.jad.2020.12.092. Epub 2020 Dec 31.Dunne J, Flores M, Gawande R, Schuman-Olivier Z. Losing trust in body sensations: Interoceptive awareness and depression symptom severity among primary care patients. J Affect Disord. 2021 Mar 1;282:1210-9. doi: 10.1016/j.jad.2020.12.092. Epub 2020 Dec 31.Таборко АД, Доманцевич ПН. Осведомленность студентов-медиков о проблеме депрессии. 2019. Доступно по ссылке: http://elib.gsmu.by:80/handle/GomSMU/5287 (дата обращения 08.12.2022).Taborko AD, Domantsevich PN. Osvedomlennost' studentov-medikov o probleme depressii [Awareness of medical students about the problem of depression]. 2019. Available from: http://elib.gsmu.by:80/handle/ GomSMU/5287 (accessed 08.12.2022) (In Russ.).Ishigooka J, Hoshino T, Imai T, et al. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey. Neuropsychiatr Dis Treat. 2021 Sep 10;17:2915-24. doi: 10.2147/NDT.S324968Ishigooka J, Hoshino T, Imai T, et al. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey. Neuropsychiatr Dis Treat. 2021 Sep 10;17:2915-24. doi: 10.2147/NDT.S324968Bell RA, Franks P, Duberstein PR, et al. Suffering in silence: reasons for not disclosing depression in primary care. Ann Fam Med. 2011 Sep-Oct;9(5):439-46. doi: 10.1370/afm.1277Bell RA, Franks P, Duberstein PR, et al. Suffering in silence: reasons for not disclosing depression in primary care. Ann Fam Med. 2011 Sep-Oct;9(5):439-46. doi: 10.1370/afm.1277Министерство здравоохранения Российской Федерации. Депрессивный эпизод, Рекуррентное депрессивное расстройство. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/301_2 (дата обращения 08.12.2022).Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Depressivnyy epizod, Rekurrentnoe depressivnoe rasstroystvo. Klinicheskie rekomendatsii [Ministry of Health of the Russian Federation. Depressive episode, Recurrent depressive disorder. Clinical guidelines]. 2021. Available from: https://cr.minzdrav.gov.ru/ recomend/301_2 (accessed 08.12.2022) (In Russ.).De Graaf R, Tuithof M, van Dorsselaer S, ten Have M. Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012 Nov;47(11):1873-83. doi: 10.1007/s00127-0120496-7. Epub 2012 Mar 21.De Graaf R, Tuithof M, van Dorsselaer S, ten Have M. Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012 Nov;47(11):1873-83. doi: 10.1007/s00127-0120496-7. Epub 2012 Mar 21.Volz HP, Bartecku E, Bartova L, et al. Sick leave duration as a potential marker of functionality and disease severity in depression. Int J Psychiatry Clin Pract. 2022 Nov;26(4):406-16. doi: 10.1080/13651501.2022.2054350. Epub 2022 Apr 2.Volz HP, Bartecku E, Bartova L, et al. Sick leave duration as a potential marker of functionality and disease severity in depression. Int J Psychiatry Clin Pract. 2022 Nov;26(4):406-16. doi: 10.1080/13651501.2022.2054350. Epub 2022 Apr 2.Miodek A, Szemraj P, Kocur J, Rys A. [Masked depression – history and present days]. Pol Merkur Lekarski. 2007 Jul;23(133):78-80.Miodek A, Szemraj P, Kocur J, Rys A. [Masked depression – history and present days]. Pol Merkur Lekarski. 2007 Jul;23(133):78-80.Смулевич АБ. Депрессии в общей медицине: Руководство для врачей. Москва: МИА; 2007. 252 c.Smulevich AB. Depressii v obshchey meditsine: Rukovodstvo dlya vrachey [Depression in General Medicine: A Guide for Physicians]. Moscow: MIA; 2007. 252 p. (In Russ.).Дробижев МЮ, Федотова АВ, Кикта СВ. Маскированные депрессии в неврологической практике. Попытка беспристрастного анализа. Фарматека. 2014;10(3):53-7.Drobizhev MYu, Fedotova AV, Kikta SV. Masked depression in neurological practice. An attempt at an unbiased analysis. Farmateka = Pharmateka. 2014;10(3):53-7 (In Russ.).Bridges KW, Goldberg DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res. 1985;29(6):563-9. doi: 10.1016/0022-3999(85)90064-9Bridges KW, Goldberg DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res. 1985;29(6):563-9. doi: 10.1016/0022-3999(85)90064-9Callahan CM, Hendrie HC, Dittus RS, et al. Depression in late life: the use of clinical characteristics to focus screening efforts. J Gerontol. 1994 Jan;49(1):M9-14. doi: 10.1093/geronj/49.1.m9Callahan CM, Hendrie HC, Dittus RS, et al. Depression in late life: the use of clinical characteristics to focus screening efforts. J Gerontol. 1994 Jan;49(1):M9-14. doi: 10.1093/geronj/49.1.m9Conde MV, Williams JW, Mulrow CD. Targeting depression interviewing: an exercise in diagnostic reasoning. J Gen Intern Med. 1998 Apr;13(4):262-5. doi: 10.1046/j.15251497.1998.00077.xConde MV, Williams JW, Mulrow CD. Targeting depression interviewing: an exercise in diagnostic reasoning. J Gen Intern Med. 1998 Apr;13(4):262-5. doi: 10.1046/j.15251497.1998.00077.xГурович ИЯ. Реформирование психиатрической помощи: организационно-методический уровень. В сб.: Материалы XIV съезда психиатров России 15–18 ноября 2005. Москва: Медпрактика-М; 2005. С. 49-50.Gurovich IYa. Reforming psychiatric care: organizational and methodological level. In: Materialy XIV s’ezda psikhiatrov Rossii 15–18 noyabrya 2005 [Proceedings of the XIV Congress of Psychiatrists of Russia November 15–18, 2005]. Moscow: Medpraktika-M; 2005. P. 49-50 (In Russ.).Закон РФ от 02.07.1992 N 3185-1 (ред. от 30.12.2021) «О психиатрической помощи и гарантиях прав граждан при ее оказании».Law of the Russian Federation of July 2, 1992 N 3185-1 (as amended on December 30, 2021) “On psychiatric care and guarantees of the rights of citizens in its provision” (In Russ.).Приказ Министерства труда и социальной защиты РФ от 29.01.2019 № 51н «Об утверждении профессионального стандарта “Врач-невролог”».Order of the Ministry of Labor and Social Protection of the Russian Federation of January 29, 2019 N 51n “On approval of the professional standard “Neurologist” (In Russ.).Проект Приказа Министерства труда и социальной защиты РФ «Об утверждении профессионального стандарта “Специалист в области психиатрии”» (подготовлен Минтрудом России 14.12.2015).Draft Order of the Ministry of Labor and Social Protection of the Russian Federation “On approval of the professional standard “Specialist in the field of psychiatry” (prepared by the Ministry of Labor of Russia on December 14, 2015) (In Russ.).Мосолов СН, Малин ДИ, Рывкин ПВ, Сычов ДА. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019;(S1):2-33. doi: 10.21265/PSYPH.2019.50.40828Mosolov SN, Malin DI, Ryvkin PV, Sychov DA. Psychotropic drugs interaction. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2019;(S1):2-33. doi: 10.21265/PSYPH.2019.50.40828 (In Russ.).Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. doi: 10.1111/j.2044-8260.1967.tb00530.xHamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. doi: 10.1111/j.2044-8260.1967.tb00530.xWilliams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7. doi: 10.1001/archpsyc.1988.01800320058007Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7. doi: 10.1001/archpsyc.1988.01800320058007Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382Mosolov S, Ushkalova A, Kostukova E, Shafarenko A, et al. Bipolar II disorder in patients with a current diagnosis of recurrent depression. Bipolar Disord. 2014 Jun;16(4):38999. doi: 10.1111/bdi.12192. Epub 2014 Mar 1.Mosolov S, Ushkalova A, Kostukova E, Shafarenko A, et al. Bipolar II disorder in patients with a current diagnosis of recurrent depression. Bipolar Disord. 2014 Jun;16(4):38999. doi: 10.1111/bdi.12192. Epub 2014 Mar 1.Mosolov SN, Ushkalova AV, Kostukova EG, Shafarenko AA, et al. Validation of the Russian version of the Hypomania Checklist (HCL-32) for the detection of Bipolar II disorder in patients with a current diagnosis of recurrent depression. J Affect Disord. 2014 Feb;155:90-5. doi: 10.1016/j.jad.2013.10.029. Epub 2013 Oct 30.Mosolov SN, Ushkalova AV, Kostukova EG, Shafarenko AA, et al. Validation of the Russian version of the Hypomania Checklist (HCL-32) for the detection of Bipolar II disorder in patients with a current diagnosis of recurrent depression. J Affect Disord. 2014 Feb;155:90-5. doi: 10.1016/j.jad.2013.10.029. Epub 2013 Oct 30.Мосолов СН. Современные биологические гипотезы рекуррентной депрессии (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(11-2):29-40.Mosolov SN. Current biological hypotheses of recurrent depression (review). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(11-2):29-40 (In Russ.).Левчук ЛА. Динамика содержания кортизола и серотонина в процессе фарма котерапии аффективных расстройств. Казань; 2015.Levchuk LA. Dinamika soderzhaniya kortizola i serotonina v protsesse farmakoterapii affektivnykh rasstroystv [Dynamics of the content of cortisol and serotonin in the process of pharmacotherapy of affective disorders]. Kazan; 2015 (In Russ.).Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206. doi: 10.1177/0004867415617657Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206. doi: 10.1177/0004867415617657Петрова НН, Маркин АВ. Открытые вопросы психотической депрессии. Современная терапия психических расстройств. 2023;(2):31-6. doi: 10.21265/PSYPH.2023.67.97.004Petrova NN, Markin AV. Open questions of psychotic depression. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2023;(2):31-6. doi: 10.21265/PSYPH.2023.67.97.004 (In Russ.).Andrade C. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Mens Sana Monogr. 2010;8(1):146-50.Andrade C. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Mens Sana Monogr. 2010;8(1):146-50.Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259-66. doi: 10.1097/JCP.0b013e3181a5233fSerretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259-66. doi: 10.1097/JCP.0b013e3181a5233fSerretti A, Mandelli L. Antidepressants and body sweight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259-72. doi: 10.4088/JCP.09r05346bluSerretti A, Mandelli L. Antidepressants and body sweight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259-72. doi: 10.4088/JCP.09r05346bluХасанова АК, Мосолов СН. Синдром отмены приема антидепрессантов (алгоритм профилактики и коррекции). Современная терапия психических расстройств. 2023;(2):37-47. doi: 10.21265/PSYPH.2023.15.79.005Khasanova AK, Mosolov SN. Antidepressant withdrawal syndrome (algorithm for the prevention and management). Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2023;(2):37-47. doi: 10.21265/PSYPH.2023.15.79.005 (In Russ.).Westenberg HGM, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants: tolerability and safety of fluvoxamine. Int J Clin Pract. 2006 Apr;60(4):482-91. doi: 10.1111/j.1368-5031.2006.00865.xWestenberg HGM, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants: tolerability and safety of fluvoxamine. Int J Clin Pract. 2006 Apr;60(4):482-91. doi: 10.1111/j.1368-5031.2006.00865.xМалин ДИ, Рывкин ПВ, Булатова ДР. Синдром удлиненного интервала QT при применении антипсихотических и антидепрессивных препаратов. Современная терапия психических расстройств. 2023;(2):48-56. doi: 10.21265/PSYPH.2023.69.57.006Malin DI, Ryvkin PV, Bulatova DR. QT prolongation syndrome with Antipsychotic and Antidepressant Drugs. Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2023;(2):48-56. doi: 10.21265/PSYPH.2023.69.57.006 (In Russ.).Костюкова ЕГ. Современные подходы к противорецидивной терапии рекуррентной депрессии. Современная терапия психических расстройств. 2021;(3):47-56. doi: 10.21265/PSYPH.2021.92.95.005Kostukova EG. Modern approaches to the relapse prevention therapy of recurrent depression. Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2021;(3):47-56. doi: 10.21265/PSYPH.2021.92.95.005 (In Russ.).Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016 Jan 22;14:9. doi: 10.1186/s12916-016-0560-3Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016 Jan 22;14:9. doi: 10.1186/s12916-016-0560-3Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ). 2016 Apr;14(2):194-206. doi: 10.1176/appi.focus.20150043. Epub 2016 Apr 7.Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ). 2016 Apr;14(2):194-206. doi: 10.1176/appi.focus.20150043. Epub 2016 Apr 7.Российское общество психиатров. Проект Клинических рекомендаций «Депрессивный эпизод, Рекуррентное депрессивное расстройство». 2023. Доступно по ссылке: https://psychiatr.ru/ (дата обращения 01.08.2023).Russian Society of Psychiatrists. Draft clinical guidelines “Depressive episode, recurrent depressive disorder”. 2023. Available from: https://psychiatr.ru/ (accessed 01.08.2023) (In Russ.).Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018 Mar;28(1):32-72. doi: 10.1007/s11065-018-9369-5. Epub 2018 Feb 14.Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018 Mar;28(1):32-72. doi: 10.1007/s11065-018-9369-5. Epub 2018 Feb 14.Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review. J Clin Psychiatry. 2020 Jul 21;81(4):19r13200. doi: 10.4088/JCP.19r13200Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review. J Clin Psychiatry. 2020 Jul 21;81(4):19r13200. doi: 10.4088/JCP.19r13200Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2018 Feb 1;21(2):97107. doi: 10.1093/ijnp/pyx070Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2018 Feb 1;21(2):97107. doi: 10.1093/ijnp/pyx070Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp. 2010 Apr;25(3):193200. doi: 10.1002/hup.1106Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp. 2010 Apr;25(3):193200. doi: 10.1002/hup.1106Bobrov A, Krasnoslobodtseva L, Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. J Psychiatry [Internet]. 2017;20(5). Available from: https://www.omicsonline.org/openaccess/effects-of-fluvoxamine-on-cognitivefunction-in-outpatients-with-depression-inremission-results-of-an-openlabel-pilot-study2378-5756-1000417.php?aid=94034 (accessed 12.08.2023).Bobrov A, Krasnoslobodtseva L, Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. J Psychiatry [Internet]. 2017;20(5). Available from: https://www.omicsonline.org/openaccess/effects-of-fluvoxamine-on-cognitivefunction-in-outpatients-with-depression-inremission-results-of-an-openlabel-pilot-study2378-5756-1000417.php?aid=94034 (accessed 12.08.2023).Mandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis. Psychiatry Clin Neurosci. 2006 Oct;60(5):598-604. doi: 10.1111/j.14401819.2006.01564.xMandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis. Psychiatry Clin Neurosci. 2006 Oct;60(5):598-604. doi: 10.1111/j.14401819.2006.01564.xKhade A, Mohamemed Bashir MS, Kale AS, Turankar A. Study of the Effect of Nortriptyline and Fluvoxamine on Psychomotor Functions in Healthy Volunteers. Indian J Psychol Med. 2010 Jul;32(2):104-7. doi: 10.4103/0253-7176.78506Khade A, Mohamemed Bashir MS, Kale AS, Turankar A. Study of the Effect of Nortriptyline and Fluvoxamine on Psychomotor Functions in Healthy Volunteers. Indian J Psychol Med. 2010 Jul;32(2):104-7. doi: 10.4103/0253-7176.78506Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2000;403:1725. doi: 10.1111/j.1600-0447.2000.tb10944.xPeretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2000;403:1725. doi: 10.1111/j.1600-0447.2000.tb10944.xRiemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5.Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5.Park SC, Kim JM, Jun TY, et al. Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study. Psychiatry Investig. 2013 Dec;10(4):37381. doi: 10.4306/pi.2013.10.4.373. Epub 2013 Dec 16.Park SC, Kim JM, Jun TY, et al. Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study. Psychiatry Investig. 2013 Dec;10(4):37381. doi: 10.4306/pi.2013.10.4.373. Epub 2013 Dec 16.Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016 Nov 5;16(1):375. doi: 10.1186/s12888016-1075-3Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016 Nov 5;16(1):375. doi: 10.1186/s12888016-1075-3Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011 Dec;135(1-3):10-9. doi: 10.1016/j.jad.2011.01.011. Epub 2011 Feb 5.Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011 Dec;135(1-3):10-9. doi: 10.1016/j.jad.2011.01.011. Epub 2011 Feb 5.Gebara MA, Siripong N, DiNapoli EA, et al. Effect of insomnia treatments on depression: A systematic review and meta-analysis. Depress Anxiety. 2018 Aug;35(8):717-31. doi: 10.1002/da.22776. Epub 2018 May 21.Gebara MA, Siripong N, DiNapoli EA, et al. Effect of insomnia treatments on depression: A systematic review and meta-analysis. Depress Anxiety. 2018 Aug;35(8):717-31. doi: 10.1002/da.22776. Epub 2018 May 21.Мосолов СН, редактор. Хронобиологическая теория аффективных расстройств. Москва: Аванпорт; 2014. 352 с.Mosolov SN, editor. Khronobiologicheskaya teoriya affektivnykh rasstroystv [Chronobiological theory of affective disorders]. Moscow: Avanport; 2014. 352 p.(In Russ.).Васильев АН, Кокин ИВ, Комарова НО. Уровень мелатонина и депрессивные расстройства. Ведомости Научного центра экспертизы средств медицинского применения. 2014;(3):24-9.Vasiliev AN, Kokin IV, Komarova MO. Melatonin levels and depressive disorders. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Scientific Centre for Expert Evaluation of Medicinal Products Bulletin. 2014;(3):24-9 (In Russ.).Wirz-Justice A, Graw P, Kräuchi K, et al. Morning or night-time melatonin is ineffective in seasonal affective disorder. J Psychiatr Res. 1990;24(2):129-37. doi: 10.1016/00223956(90)90053-sWirz-Justice A, Graw P, Kräuchi K, et al. Morning or night-time melatonin is ineffective in seasonal affective disorder. J Psychiatr Res. 1990;24(2):129-37. doi: 10.1016/00223956(90)90053-sUsov GM, Kolomytsev DYu, Lomiashvili LM. Impact of different classes of antidepressants on sleep and wakefulness regulation in depression. RJTAO. 2022 Feb 26;14(1):82-8.Usov GM, Kolomytsev DYu, Lomiashvili LM. Impact of different classes of antidepressants on sleep and wakefulness regulation in depression. RJTAO. 2022 Feb 26;14(1):82-8.Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. 4th ed. Cambridge; New York: Cambridge University Press; 2013. 608 p.Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. 4th ed. Cambridge; New York: Cambridge University Press; 2013. 608 p.Никитина АЮ, Левин ОС. Применение тразодона при нейропсихиатрических расстройствах у пожилых. Современная терапия психических расстройств. 2022;(4):43-8. doi: 10.21265/PSYPH.2022.60.29.006Nikitina AYu, Levin OS. The Use of Trazodone in neuropsychiatric Disorders in the Elderly. Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2022;(4):43-8. doi: 10.21265/PSYPH.2022.60.29.006 (In Russ.).Sunami E, Usuda K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med. 2012;51(10):1187-93. doi: 10.2169/internalmedicine.51.6699. Epub 2012 May 15.Sunami E, Usuda K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med. 2012;51(10):1187-93. doi: 10.2169/internalmedicine.51.6699. Epub 2012 May 15.Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi: 10.2147/NSS.S220947. eCollection 2019.Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi: 10.2147/NSS.S220947. eCollection 2019.Härtter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714200104000-00008Härtter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714200104000-00008Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry. 2003 Jun;160(6):1147-56. doi: 10.1176/appi.ajp.160.6.1147Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry. 2003 Jun;160(6):1147-56. doi: 10.1176/appi.ajp.160.6.1147Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep. 1999 Jun 30;47(19):1-104.Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep. 1999 Jun 30;47(19):1-104.Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: Медицинское информационное агентство; 1995. 568 c.Mosolov SN. Klinicheskoye primeneniye sovremennykh antidepressantov [Clinical use of modern antidepressants]. St. Petersburg: Medical Information Agency; 1995. 568 p. (In Russ.).Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD003491. doi: 10.1002/14651858.CD003491.pub2Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD003491. doi: 10.1002/14651858.CD003491.pub2Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754-62. doi: 10.1002/gps.1156Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754-62. doi: 10.1002/gps.1156Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000 May 2;132(9):743-56. doi: 10.7326/0003-4819-1329-200005020-00011Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000 May 2;132(9):743-56. doi: 10.7326/0003-4819-1329-200005020-00011Wiese B. Geriatric depression: The use of antidepressants in the elderly. BCMJ. 2011;53(47):341-7.Wiese B. Geriatric depression: The use of antidepressants in the elderly. BCMJ. 2011;53(47):341-7.Center for Drug Evaluation and. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). FDA [Internet]. 2021 Jan 7. Available from: https://www.fda.gov/drugs/drug-safety-andavailability/fda-drug-safety-communicationabnormal-heart-rhythms-associated-highdoses-celexa-citalopram (accessed 08.12.2022).Center for Drug Evaluation and. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). FDA [Internet]. 2021 Jan 7. Available from: https://www.fda.gov/drugs/drug-safety-andavailability/fda-drug-safety-communicationabnormal-heart-rhythms-associated-highdoses-celexa-citalopram (accessed 08.12.2022).Хасанова АК. Применение антидепрессантов и риск падения у пациентов старшего возраста. Современная терапия психических расстройств. 2022;(4):25-33. doi: 10.21265/PSYPH.2022.74.75.004Khasanova АK. Antidepressant use and risk of falls in elderly patients. Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2022;(4):25-33. doi: 10.21265/PSYPH.2022.74.75.004 (In Russ.).Agüera-Ortiz L, Claver-Martin MD, Franco-Fernändez MD, et al. Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association. Front Psychiatry. 2020 May 20;11:380. doi: 10.3389/fpsyt.2020.00380. eCollection 2020.Agüera-Ortiz L, Claver-Martin MD, Franco-Fernändez MD, et al. Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association. Front Psychiatry. 2020 May 20;11:380. doi: 10.3389/fpsyt.2020.00380. eCollection 2020.Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:12-20. doi: 10.1007/s00406-007-1004-zMaier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:12-20. doi: 10.1007/s00406-007-1004-zZhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030000000000-00000Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030000000000-00000Чучалин АГ, Яснецов ВВ, редакторы. Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. XIII. Москва; 2012.Chuchalin AG, Yasnetsov VV, editors. Federal'noye rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) [Federal Guidelines for the Use of Medicines (formulary system)]. Is. XIII. Moscow; 2012 (In Russ.).Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008 Oct;82(10):667-715. doi: 10.1007/s00204008-0332-8. Epub 2008 Jul 11.Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008 Oct;82(10):667-715. doi: 10.1007/s00204008-0332-8. Epub 2008 Jul 11.Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742Михеенкова НМ, Рывкин ПВ, Мосолов СН. Серотониновый синдром: клиника, патофизиология и терапия. Современная терапия психических расстройств. 2022;(2):53-63. doi: 10.21265/PSYPH.2022.90.61.006 (In Russ.).Mikheenkova NM, Ryvkin PV, Mosolov SN. Serotonin syndrome: clinical aspects, pathophysiology and treatment. Sovremennaya terapiya psikhicheskikh rasstrojstv = Current Therapy of Mental Disorders. 2022;(2):53-63. doi: 10.21265/PSYPH.2022.90.61.006 (In Russ.).

The authors declare that there are no conflicts of interest present.